\-\ Texto\\:\\ \ \(0\)\
\-\ examination\\:\\ perioral\\:\\ discreet\\,\\ confluent\\,\\ violaceous\\ firm\\ papules\ \(0\)\
\-\ course\\:\\ tetracycline\\ 500\\ mg\\ twice\\ a\\ day\\ for\\ one\\ month\\;\\ and\\ prednisone\\ taper\\ 40\\ mg\\ over\\ 14\\ days\\.\ \(0\)\
\-\ histopathology\\:\\ the\\ biopsy\\ shows\\ acute\\ and\\ granulomatous\\ inflammation\\ of\\ the\\ dermis\\.\\ special\\ stains\\ for\\ infectious\\ etiologies\\ were\\ negative\\.\ \(0\)\
\-\ case\\ 27\\ \\(27th\\ annual\\ uniformed\\ services\\ dermatology\\ seminar\\,\\ 2003\\)\\ perioral\\ granulomatous\\ dermatitis\ \(0\)\
\-\ history\\:\\ 12\\ year\\ old\\ african\\ american\\ male\\ with\\ a\\ three\\ month\\ history\\ of\\ perioral\\ rash\\ that\\ worsened\\ with\\ application\\ of\\ hydrocortisone\\ 1\\%\\,\\ hydrocortisone\\ valerate\\ 0\\.2\\%\\ and\\ pimecrolemus\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ perioral\\:\\ 0\\.467337942532166\ \(0\)\
\-\ hydrocortisone\\:\\ 0\\.3115586283547773\ \(0\)\
\-\ granulomatous\\:\\ 0\\.19251609523219407\ \(0\)\
\-\ mg\\:\\ 0\\.18904789905817967\ \(0\)\
\-\ valerate\\:\\ 0\\.17317331370143527\ \(0\)\
\-\ pimecrolemus\\:\\ 0\\.17317331370143527\ \(0\)\
\-\ discreet\\:\\ 0\\.16001526101209537\ \(0\)\
\-\ tetracycline\\:\\ 0\\.15577931417738866\ \(0\)\
\-\ taper\\:\\ 0\\.14685720832275548\ \(0\)\
\-\ violaceous\\:\\ 0\\.1408119828775772\ \(0\)\
\-\ application\\:\\ 0\\.13492429408227175\ \(0\)\
\-\ month\\:\\ 0\\.1317435747010891\ \(0\)\
\-\ dermatitis\\:\\ 0\\.13043691234838786\ \(0\)\
\-\ stains\\:\\ 0\\.12853702231354663\ \(0\)\
\-\ 27th\\:\\ 0\\.1276539301882373\ \(0\)\
\-\ confluent\\:\\ 0\\.12522726196400213\ \(0\)\
\-\ papules\\:\\ 0\\.1237663061054245\ \(0\)\
\-\ special\\:\\ 0\\.1237663061054245\ \(0\)\
\-\ 500\\:\\ 0\\.12307593702998373\ \(0\)\
\-\ dermis\\:\\ 0\\.12240979649307471\ \(0\)\
\-\ twice\\:\\ 0\\.12176624139293185\ \(0\)\
\-\ rash\\:\\ 0\\.1167857655106317\ \(0\)\
\-\ prednisone\\:\\ 0\\.11406927398715486\ \(0\)\
\-\ histopathology\\:\\ 0\\.10925174380373481\ \(0\)\
\-\ seminar\\:\\ 0\\.10892723919469295\ \(0\)\
\-\ etiologies\\:\\ 0\\.10860818870359196\ \(0\)\
\-\ uniformed\\:\\ 0\\.10798573761603147\ \(0\)\
\-\ worsened\\:\\ 0\\.10798573761603147\ \(0\)\
\-\ services\\:\\ 0\\.10623220958120447\ \(0\)\
\-\ dermatology\\:\\ 0\\.10595507973436666\ \(0\)\
\-\ annual\\:\\ 0\\.10008574092344093\ \(0\)\
\-\ firm\\:\\ 0\\.09816662753772891\ \(0\)\
\-\ african\\:\\ 0\\.09780503455994496\ \(0\)\
\-\ 2003\\:\\ 0\\.09745020072674469\ \(0\)\
\-\ american\\:\\ 0\\.09238877351766395\ \(0\)\
\-\ 27\\:\\ 0\\.08775316860847505\ \(0\)\
\-\ infectious\\:\\ 0\\.08713071752091457\ \(0\)\
\-\ inflammation\\:\\ 0\\.0870289314466863\ \(0\)\
\-\ history\\:\\ 0\\.08274324494607813\ \(0\)\
\-\ 14\\:\\ 0\\.08084578054105875\ \(0\)\
\-\ course\\:\\ 0\\.07998602346154299\ \(0\)\
\-\ 40\\:\\ 0\\.07963897435568687\ \(0\)\
\-\ biopsy\\:\\ 0\\.07590481155618704\ \(0\)\
\-\ 12\\:\\ 0\\.07402376326717322\ \(0\)\
\-\ three\\:\\ 0\\.07269020457561165\ \(0\)\
\-\ examination\\:\\ 0\\.06929288559909282\ \(0\)\
\-\ day\\:\\ 0\\.06897649398569947\ \(0\)\
\-\ days\\:\\ 0\\.0685498904739569\ \(0\)\
\-\ and\\:\\ 0\\.067128093521811\ \(0\)\
\-\ negative\\:\\ 0\\.06703928713647692\ \(0\)\
\-\ for\\:\\ 0\\.06564147246788833\ \(0\)\
\-\ of\\:\\ 0\\.06357342901414738\ \(0\)\
\-\ shows\\:\\ 0\\.06355467046869212\ \(0\)\
\-\ one\\:\\ 0\\.06199897064552048\ \(0\)\
\-\ over\\:\\ 0\\.06021192478093912\ \(0\)\
\-\ acute\\:\\ 0\\.05857873002002067\ \(0\)\
\-\ were\\:\\ 0\\.055818441296359565\ \(0\)\
\-\ case\\:\\ 0\\.054401842643198466\ \(0\)\
\-\ male\\:\\ 0\\.04821321131560682\ \(0\)\
\-\ that\\:\\ 0\\.04699217864320499\ \(0\)\
\-\ the\\:\\ 0\\.043214067662574254\ \(0\)\
\-\ with\\:\\ 0\\.04240760941522308\ \(0\)\
\-\ year\\:\\ 0\\.03337169527976718\ \(0\)\
\-\ old\\:\\ 0\\.03204837936757616\ \(0\)\
